Trial Profile
A Multiple Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Multiple Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs NN 9277 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 16 Dec 2022 Results assessing prevalence of arrhythmias in participants with overweight or obesity from two clinical studies: NCT03661879 and NCT03308721 published in the Journal of Clinical Pharmacology
- 10 Jan 2020 Status changed from active, no longer recruiting to completed.
- 21 Oct 2019 Status changed from recruiting to active, no longer recruiting.